Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients

Affiliations

¹ aInstitute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome bDivision of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan cDivision of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence dInfectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan eInfectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome fInstitute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona gDepartment of Clinical and Experimental Medicine, University of Sassari, Sassari hUniversity Division of Infectious Diseases, Siena University Hospital, Siena, Italy.

Comment

Alberto Borghetti et al. AIDS. 2017.

. 2017 Jan 28;31(3):457-459.

doi: 10.1097/QAD.0000000000001357.

¹ aInstitute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome bDivision of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan cDivision of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence dInfectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan eInfectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome fInstitute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona gDepartment of Clinical and Experimental Medicine, University of Sassari, Sassari hUniversity Division of Infectious Diseases, Siena University Hospital, Siena, Italy.

No abstract available

Comment in

Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe.
Menard A, Montagnac C, Solas C, Meddeb L, Dhiver C, Tomei C, Ravaux I, Tissot-Dupont H, Mokhtari S, Colson P, Stein A. Menard A, et al. AIDS. 2017 May 15;31(8):1201-1203. doi: 10.1097/QAD.0000000000001459. AIDS. 2017. PMID: 28441180 No abstract available.
Dolutegravir and neuropsychiatric adverse events: a continuing debate.
Cailhol J, Rouyer C, Alloui C, Jeantils V. Cailhol J, et al. AIDS. 2017 Sep 10;31(14):2023-2024. doi: 10.1097/QAD.0000000000001596. AIDS. 2017. PMID: 28857781 No abstract available.

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice.
de Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, Brinkman K. de Boer MG, et al. AIDS. 2016 Nov 28;30(18):2831-2834. doi: 10.1097/QAD.0000000000001279. AIDS. 2016. PMID: 27824625